Cancer Genetics, Inc. (NASDAQ: CGIX) is focused on the
development of personalized genetic testing for the detection of various
cancers, with the goal of significantly increasing treatment efficacy while
reducing healthcare costs. CGI’s scientific advisory board includes leaders in
the areas of hematological malignancies, solid tumor cancers, pharmacogenomics,
and clinical trials administration. The company’s growing patent base consists
of molecular-focused patents for the diagnosis, prognosis, and risk
stratification of difficult-to-treat cancers, based on what the company calls
“unique algorithms that take into account multiple chromosomal regions
associated with particular disease outcomes or treatment decision”.
CGI is heavily involved in the area of pharmacogenomics –
determining the way genetics affects a patient’s drug response – to improve
treatment and even help select trial populations for clinical testing. The
company offers a number of pharmacogenomics testing services, including
theranostic testing for various hematological and solid tumor cancers. In 2013,
CGI helped form Oncospire Genomics as an equally owned joint venture with Mayo
Clinic, designed to develop and commercialize NGS (Next Generation Sequencing)
panels for unmet critical oncological needs. In 2014, CGI acquired Gentris,
LLC, a pharmacogenomics testing, genotyping, and biorepository services company
based in Raleigh, NC, with operations in China. That same year, the company
also acquired India-based Bioserve Biotechnologies Pvt. Ltd., a leader in DNA
related services in India.
Based in Rutherford, New Jersey, CGI also has operations in
North Carolina and California, as well as in India and China. In addition, the
company has research collaborations with cancer research and treatment leaders
around the world, including:
Beth Israel Deaconess Medical Center
Cleveland Clinic
Columbia University
Groupe Hospitalier Pitié Salpétriêre, Paris
Huntsman Cancer Institute, University of Utah
Kamineni Hospital
Keck Medicine of USC
Mayo Clinic
Memorial Sloan-Kettering Cancer Center
Moffitt Cancer Center
National Cancer Institute
North Shore-Long Island Jewish Health System
University of Alabama School of Medicine
University of Iowa Cancer Center
Westchester Medical Center at New York Medical College
CGI’s President and CEO is Panna Sharma, founder of TSG
Partners, a specialty life sciences consultancy and advisory company, where he
directed the company’s strategic initiatives and growth strategy, including various
public and private company turnarounds, establishing several life science
capital markets indices that are still used in the life science industry.
For more information, visit www.CancerGenetics.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
